World's Largest Hyaluronic Acid Giant Bloomage Bio Establishes a Medical Venture
- Chaileedo Press
- Jun 22, 2022
- 3 min read
Bloomage Biotech, the global hyaluronic acid giant, has joined hands with Rohto Pharmaceutical Co., Ltd and BioMimetics Sympathies(BMS) to establish a joint venture. The main business is to carry out research in the field of regenerative medicine and cell culture medium while conducting commercial operations.
According to CHAILEEDO, on June 21, China Standard Time, Bloomage Bio news: Bloomage Biotechnology (Hainan) Co., Ltd., a subsidiary of Bloomage Bio, and Rohto Pharmaceutical Co., Ltd. ("Rohto" for short), BioMimetics Sympathies ("BMS" for short) has officially reached a strategic cooperation and plans to establish a joint venture company with relevant parties. This also marks Bloomage Bio's official entry into the field of regenerative medicine.
According to the official website, Bloomage Bio is a hyaluronic acid industry chain platform company integrating R&D, production, and sales. In 2007, Bloomage Bio became the world's largest hyaluronic acid producer. Bloomage Bio has established a whole industry chain business system of bioactive materials from raw materials to medical end products, functional skin care products, and functional foods. Among them, functional skin care products include Biohyalux, QuadHA, MedRepair, Bio-MESO, and other brands.
It is reported that the joint venture company established by Bloomage Bio will be located in Haikou High-tech Zone, Hainan, China. The relevant person in charge of Bloomage Bio said that Hainan Free Trade Port is one of the key links in the strategic layout of Bloomage Bio. At the end of 2020, Bloomage Bio settled in Hainan Free Trade Port and built the Bloomage Biotechnology Industrial Park, which has been listed as a key project in Hainan Province in 2022.
The joint venture company will be stationed in the industrial park and will give priority to the field of mesenchymal stem cell culture medium. At the same time, Bloomage Bio will build a regenerative medicine production line in the industrial park, assisting the joint venture company to form an industrial ecological chain from R&D to industrialization and commercial operation.
In addition, Bloomage Biotechnology Industrial Park will also simultaneously invest in planning a GMP-level cell culture medium production line to support the production of related products of the joint venture company in the future.
Cell culture medium has always been known as the "chip power" of the global biopharmaceutical industry. The preparation and production of biological products are highly dependent on the cell culture medium. At the same time, the cell culture medium is also a key consumable for scientific research in the fields of biology and medicine.
In recent years, due to the rapid development of the global biopharmaceutical industry and the impact of COVID-19, the research and development of antibody drugs, vaccines, and cell therapy products has shown a rapid growth trend, driving the rapid development of the upstream industry of biological products, and the market demand for culture medium has increased significantly.
The partner, Rohto Pharma, is a Japanese pharmaceutical company whose business scope covers eye drops, pharmaceuticals, cosmetics, and functional foods. BMS is a regenerative medicine research and development enterprise that conducts customized cell culture media for cell-targeted therapy of specific diseases. Its culture medium is characterized by not using raw materials of human or animal origin, contributing to the development of regenerative medicine by providing professional cell culture technology while being safe and effective.
Through this cooperation, Bloomage Bio has officially entered the field of regenerative medicine. The layout of the regenerative medicine and cell culture medium industry is another important strategic layout of Bloomage Bio in the underlying scientific research, which will further enrich the core technology matrix of Bloomage Bio. At the same time, this move will further enhance the core technical strength of China's regenerative medicine and cell culture medium industries and bring a strong momentum to the development of the Hainan Free Trade Port.
Comments